Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136752 | 1.00 | AKR1B1 (0.37) | AKR1B1MPI | |
| SCHEMBL1735271 | 1.00 | AKR1B1 (0.37) | AKR1B1MPI | |
| SCHEMBL8891159 | 1.00 | AKR1B1 (0.37) | AKR1B1MPI | |
| SCHEMBL3357554 | 0.94 | AKR1B1 (0.36) | AKR1B1MPI | |
| SCHEMBL2319489 | 0.94 | AKR1B1 (0.36) | AKR1B1MPI | |
| SCHEMBL2323870 | 0.94 | AKR1B1 (0.36) | AKR1B1MPI | |
| SCHEMBL2319597 | 0.94 | AKR1B1 (0.36) | AKR1B1MPI | |
| Phosphoric Acid SCHEMBL10786308 | 0.92 | MPI (0.43) | AKR1B1MPI | |
| SCHEMBL6219720 | 0.78 | AKR1B1 (0.37) | AKR1B1MPI | |
| SCHEMBL19480788 | 0.78 | AKR1B1 (0.37) | AKR1B1MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264672-A1 | INHIBITORS OF MOBILIZED COLISTIN RESISTANCE ENZYME (MCR-1) AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250302846-A1 | ANTIBIOTIC COMPOSITION AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-10-02 | — | — | US | disclosed |
| US-20250270657-A1 | Detection of Antibiotic Resistance Genes | STRECK, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250170127-A1 | RE-SENSITIZING MULTIDRUG-RESISTANT (MDR) GRAM-NEGATIVE BACTERIA TO COLISTIN USING IONOPHORES | UNIV COLORADO REGENTS (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250074945-A1 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | UNIV UTAH RES FOUND (US) | 2025-03-06 | — | — | US | disclosed |
| US-12215129-B2 | Antibacterial cyclopeptides targeting acinetobacter and other gram-negative pathogens | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4482494-A1 | RE-SENSITIZING MULTIDRUG-RESISTANT (MDR) GRAM-NEGATIVE BACTERIA TO COLISTIN USING IONOPHORES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024243062-A1 | DETECTION OF ANTIBIOTIC RESISTANCE GENES | STRECK LLC (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20230391827-A1 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | NATIONAL INSTITUTES OF HEALTH | 2023-12-07 | — | — | US | disclosed |
| WO-2023220324-A1 | ANTIBIOTIC COMPOSITION AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2021099513-A1 | METHOD FOR PREDICTING THE VIRULENCE AND PATHOGENICITY OF GRAM-NEGATIVE BACTERIAL STRAINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-05-27 | — | — | WO | disclosed |
| WO-2020243644-A9 | DETECTION OF ANTIBIOTIC RESISTANCE GENES | STRECK, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020243644-A1 | DETECTION OF ANTIBIOTIC RESISTANCE GENES | STRECK, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020023620-A1 | METHODS AND COMPOSITIONS OF CHEMICALLY MODIFIED PHAGE LIBRARIES | TRUSTEES OF BOSTON COLLEGE (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2019237186-A1 | PREPARATION OF DILIPID POLYMYXINS AND USE THEREOF AS ANTIMICROBIAL ADJUVANTS | UNIVERSITY OF MANITOBA (CA) | 2019-12-19 | — | — | WO | disclosed |
| US-9296995-B2 | Vaccines against Bordetella pertussis based on LPS glycosyltransferase mutants | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2016-03-29 | — | — | US | disclosed |
| EP-2134743-B1 | IMPROVED VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS | NEDERLANDEN STAAT (NL) | 2012-09-05 | — | — | EP | disclosed |
| US-20100291153-A1 | VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2010-11-18 | — | — | US | disclosed |
| EP-2134743-A2 | IMPROVED VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS | De Staat der Nederlanden, vert. door de minister van VWS (NL) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008118015-A2 | IMPROVED VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074945-A1 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | DNPEP, PIN1, PPIA | AKR1B1 2421/4885MPI 34/4885 |
| US-20250170127-A1 | RE-SENSITIZING MULTIDRUG-RESISTANT (MDR) GRAM-NEGATIVE BACTERIA TO COLISTIN USING IONOPHORES | MCRS1, MRPS18A, NPEPPS | AKR1B1 4722/4885MPI 384/4885 |
| US-20230391827-A1 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | DNPEP, PIN1, PPIA | AKR1B1 2421/4885MPI 34/4885 |
| US-20250302846-A1 | ANTIBIOTIC COMPOSITION AND METHODS OF USE THEREOF | SPOUT1, CUTA, MYD88 | AKR1B1 4724/4885MPI 1679/4885 |
| US-12215129-B2 | Antibacterial cyclopeptides targeting acinetobacter and other gram-negative pathogens | DNPEP, PIN1, PPIA | AKR1B1 2421/4885MPI 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.